Interview with Dr. Robert Hewitt, Biosample Hub

The pharmaceutical industry has the infrastructural and financial resources to bring novel drugs and vaccines into the clinic. It would greatly help expedite their timeline if they had access to biobanks at academic institutes, in order to better understand...

A Biobank Cost Model: Shanghai Birth Cohort Study

The infrastructure required for biobanking is costly and often depends on government funds to some extent. Resources for establishing cost are available, such as the biospecimen user fee calculator tool developed by the Canadian Tissue Repository Network...

🔥 Most Popular

Featured Vendors